AGEN:
Analysis & Opinions
-
February 14, 2013
ImmunoGen, Inc. (IMGN) recently announced that it has finished enrolling patients for the initial stage of the ...
-
February 07, 2013
Seattle Genetics Inc. (SGEN) recently commenced two phase I clinical studies with its oncology candidate, SGN-CD19A. ...
-
January 30, 2013
Anacor Pharmaceuticals, Inc. (ANAC) recently announced positive preliminary results on tavaborole (AN2690) from ...
-
January 29, 2013
Threshold Pharmaceuticals, Inc. (THLD) and Merck KGaA (MKGAF) recently announced the commencement of a global phase ...
-
January 25, 2013
Cadence Pharmaceuticals Inc. (CADX) recently announced that it expects preliminary net revenue of Ofirmev ...
-
January 25, 2013
Seattle Genetics Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TKPYY) recently announced the commencement ...
-
January 16, 2013
InterMune Inc. (ITMN) recently announced its intention to raise funds through concurrent underwritten public ...
-
January 14, 2013
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $100.00. The ...
-
January 10, 2013
Orexigen Therapeutics, Inc. (OREX) recently provided an update on its obesity candidate, Contrave. The company, ...
-
January 10, 2013
BioMarin Pharmaceutical Inc. (BMRN) recently acquired privately held biotechnology company, Zacharon ...
-
January 10, 2013
The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase ...
-
August 14, 2012
With earnings season underway, I've been running screens with the concept to find companies that have just recently ...
-
April 11, 2012
The risks are huge, but well worth the potential rewards, writes MoneyShow.com senior editor Igor Greenwald. ...
-
July 19, 2011
Vical gets a small victory with a partnership for its CMV drug.
-
April 11, 2008
Russia approved U.S. biotech Antigenics' kidney cancer vaccine. The dawn of a potentially lucrative market may be at ...
